Navigation Links
Inhibiting prostate cancer without disturbing regular body processes
Date:8/9/2010

This release is available in French.

Inhibiting prostate cancer without disturbing regular body processes Researchers explain how a facultative enzyme governs tumour growth

A kinase is a type of enzyme the body uses to regulate the functions of the proteins required for cell growth and maintenance, and researchers have discovered that one in particular plays a key role in developing prostate cancer. "It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth" said Dr. Luc Furic, a postdoctoral researcher working with Dr. Nahum Sonenberg at McGill University's Goodman Cancer Research Centre and Department of Biochemistry.

This is a very significant finding because the body's chemical processes are highly complex and interrelated, meaning that targeting one cause of cancer often involves affecting the body's normal functions. An important part of cancer research is about trying to find processes that can be inhibited or stopped without causing damages to normal tissue.

The chemical process Mnk uses is known as phosphorylation, and this process activates or inactivates the body's proteins, controlling mechanisms that can cause disease. In this case, Mnk works with a protein known as eIF4E to synthesize proteins in the cell.

Researchers at the Centre hospitalier de l'Universit de Montral Research Centre (CRCHUM), Universit de Montral and McGill University engineered mice that were able to block the phosphorylation process of this protein, and discovered that these mice became resistant to prostate cancer growth. "The PTEN gene and its protein act as a tumour suppressor," explained Dr. Fred Saad, researcher at the CRCHUM and at Universit de Montral's Department of Surgery. "By removing this gene in the mouse prostate, we were able to study eIF4E's effect on cell growth."

The research is directly related to humans, because PTEN is frequently mutated in human prostate cancer. Studies on cancer patients have confirmed eIF4E's involvement.

The task ahead will be to find a specific and selective pharmacological inhibitor of Mnks. Although some inhibitors are used for research purposes, these inhibitors are not highly specific to this kinase.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related medicine news :

1. Inhibiting fatty acids in immune cells decreases atherosclerosis risk
2. Advance Toward Test for Aggressive Prostate Cancer
3. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
4. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
5. Few differences in outcomes between open and laparoscopic prostate surgery
6. Two Surgical Methods Equally Successful for Prostate Cancer
7. Genetic Mutation Linked to Prostate Cancer in Blacks
8. Statins May Benefit Prostate Cancer Patients
9. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
10. Be a Star Athlete in the Fight Against Prostate Cancer
11. Do men with early prostate cancer commit suicide more frequently?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... announced the appointment of Mike Finnegan to the position of Executive Vice President, ... of experience in healthcare technology, telehealth and medical device sales leadership. He has ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands ... whether they can trust the sponsor to pay them correctly and on time. As ... CROs establish payment strategies that encourage sites to work on their studies. , At ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... solution for many of the health care industry’s hospitals and provider groups, has ... financing portal for select customers. Parasail Health is a San Francisco health-finance startup ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the success ... became the sixth state to pass legislation which ensures that children can possess ... Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who have ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article on medGadget ... $6.81 billion by the year 2024 according to a new report. The article also ... made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with ... be presenting at the 7th annual LD Micro Invitational on Tuesday, ... CEO, of DarioHealth will be giving the presentation and meeting with ... & 7th, 2017 at the Luxe Sunset Bel Air Hotel and ... About LD Micro LD Micro was ...
Breaking Medicine Technology: